All News
ACR21 Best Abstracts We Saw - Day 3 (Monday)
The third day of ACR 2021 took a big leap in online content. Here is a compilation (with links) of presentations were the “ACRBest” as seen by our RheumNow faculty.
Read Article
SELECT-EARLY results for #upadacitinib in #RA
👉🏼UPA better than MTX for clinical response and remission
👉🏼⬆️rates of HZ, neutropenia, CPK elevations
👉🏼No new safety risks identified
Abs#1692 #ACR21 @RheumNow
https://t.co/wJy7MK4pyF https://t.co/YNpE1Axiw0
Mrinalini Dey DrMiniDey ( View Tweet)
The Influence of Obesity on Choice of Biologic Agent in Rheumatoid Arthritis
Dr. Richard Conway ( @RichardPAConway) reviews an abstract presented at #ACR21.
https://t.co/PkJmpODz8v https://t.co/zuJjofka3B
Links:
Dr. John Cush RheumNow ( View Tweet)
Adults with #JIA #uveitis are still affected into adulthood. @Mara_Becker discusses visual outcomes #ACR21 https://t.co/ZBjw1CfSmv
Sheila Angeles-Han STHanMD ( View Tweet)
Prof. Cornelia Weyand wonderfully summarizes the mechanisms behind the premature immune #aging phenotype in #RheumatoidArthritis leading to tissue #Inflammation
🔸defect in mitoDNA repair
🔸expanded rough ER
🔸⬇ protein myristoylation
@RheumNow #ACR21 #RheumTwitter https://t.co/8cyqLscctB
sheila RHEUMarampa ( View Tweet)
Can you stop monitoring eyes in + ANA and/or pauciarticular pt who becomes an adult if no uveitis ever, in last 5 yrs, etc. When can we stop looking? #AVR21 @RheumNow https://t.co/1Ml1BuJD7Y
Janet Pope Janetbirdope ( View Tweet)
#ACR21 Year In Review highlighted the need to combat the root causes of socioeconomic disparities to improve functional status in #rheumatoid #arthritis @RheumNow https://t.co/MKgh7UEP8b https://t.co/Vg2jyfuDnf
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Dr McDermott @jeffsparks on risk factors for RA-bronchiectasis. Seropositivity, older age at RA onset, and lower BMI⬆️risk. Abstr#0288 #ACR21 @RheumNow https://t.co/7d2ZVWLzn6
Richard Conway RichardPAConway ( View Tweet)
Dr O'Brien on co-existent AAV and RA. Not something I'm used to seeing, but maybe we need to think about it more? 25 cases with RA+AAV, 52 with RA + ANCA but no AAV, not sure what the denominator is here though. Abstr#0428 #ACR21 @RheumNow @profgayecunnane https://t.co/fN3BRpc7UJ
Richard Conway RichardPAConway ( View Tweet)
Dr Adachi presents ⬆️BMD gain with denosumab than risedronate in RA. Non-significant reduction in fractures (very small numbers) Interesting, but need to see fracture benefit in larger study to justify dmab as first line Abstr#0445 #ACR21 @RheumNow https://t.co/GgaS9JZGzb
Richard Conway RichardPAConway ( View Tweet)
Diabetes puts you at risk of cardiovascular disease, right?
What about RA?
Look at this graph and compare the pair.
"already it was impossible to say which was which” - George Orwell, Animal Farm
#ACR21 ABST0287 @RheumNow https://t.co/r0yaeC530l https://t.co/mKJhoyJ2Cn
David Liew drdavidliew ( View Tweet)
Year 2 f/u on PsA, axSpA, or RA using CT-P13, an infliximab (IFX) biosimilar. Pts either naive to IFX or switched from IFX:
💠IFX-naive: improved disease activity
💠IFX-switched: maintained stable disease
💠No new safety concerns
https://t.co/VGBicnq15w
#ACR21 Abst#0817 @RheumNow
Pedro Castillo _Castillo_Pedro ( View Tweet)
Interesting question came up: why would you change a RA patient from JAKi to JAKi?
The main reason I can think of would be if the first JAKi worked a bit (but not enough to continue, or AEs got in the way).
That would clearly favour to better survival
#ACR21 ABST1442 @RheumNow https://t.co/kDiJVbJfit
David Liew drdavidliew ( View Tweet)
Loved this session on: Preclinical Rheumatoid Arthritis- Can we stop RA? As a patient advocate living with RA, my providers have always ran tests on my microbiome. The findings have correlated with my disease flares, and was a big trigger overall. #ACR21 @ACRheum Thank you! https://t.co/6hm6hr85JS
Effie Koliopoulos RisingAboveRa ( View Tweet)
MRI Imaging in RA and SpA: Dr. Sheila Reyes ( @RHEUMarampa)
Dr. Sheila Reyes discusses abstracts #0468 and #0469, presented at the #ACR21 annual meeting.
https://t.co/MeVia60BNa https://t.co/WRgCifpioQ
Links:
Dr. John Cush RheumNow ( View Tweet)
Alcohol and MTX don't go along!
In a cohort of 1000+ early RA
Factors associated w/
1️⃣Nausea
Female OR 2
🍺 Alcohol OR 1.44
DAS28CRP OR 1.16
2️⃣Alopecia
Age OR 4.87
🍺 Alcohol OR 1.98
HAQ score OR 1.62
#Abst1444 #ACR21 @RheumNow https://t.co/zZG6aFR1SX
Aurelie Najm AurelieRheumo ( View Tweet)
Rheumatology Research Foundation Lecture: Learning lessons from @Google to harness #omics to better understand #RA
#ACR21 @RheumNow @RheumResearch https://t.co/NVAe2Rqo1O
Mrinalini Dey DrMiniDey ( View Tweet)
@NamrataRheum on outcomes in RA patients on RTX who get COVID-19. ⬆️hospitalisation, ICU, mech ventilation, but not mortality (in this cohort) Abstr#1445 #ACR21 @RheumNow https://t.co/8RcrzTdEb0
Richard Conway RichardPAConway ( View Tweet)
Yup, another large database shows more #hospitalizations with #RheumatoidArthritis with #rituximab but NOT higher mortality in matched analysis. Abst#1445 #ACR21 @RheumNow https://t.co/9XV8iX10sA
Janet Pope Janetbirdope ( View Tweet)
You can <but not as frequently> treat to target in #RheumatoidArthritis with virtual v in person visits. 45 docs in 18 practices comparing in person to virtual. In person wins but not by a large gap! Abst#1448 @dansolomon @RheumNow #ACR21 #ACRBest session today coming up https://t.co/8lcuMW0bwb
Janet Pope Janetbirdope ( View Tweet)
